All Ablynx articles
-
BusinessSanofi enters M&A bonanza
French drugmaker strengthens rare diseases portfolio with blood disorder purchases
-
Business
Grabbing slices of the immuno-oncology pie
Another spate of immuno-oncology dealmaking adds to fervour in pharma’s ‘hottest space’
-
Business
Merck & Co doubles up on Ablynx research deal
Cancer nanobody R&D partnership could be worth €1.7 billion
-
Business
Nanobody inflammation drug attracts Abbvie
$840m licensing deal shows support for antibody fragments